Healthcare -
Medical - Diagnostics & Research - NASDAQ - US
$ 12.39
-1.04 %
$ 1.13 B
Market Cap
-9.68
P/E
Price Target
Average
139.82%
Revenue Forecast
Estimate
11.86%
EBIT
Estimate
9.12%
Net Income
Estimate
32.03%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Myriad Genetics, Inc.
Wall Street analysts predict an average 1-year price target for MYGN of $29.7 , with forecasts ranging from
a
low of
$21 to a high of $35 .
MYGN Lowest Price Target
Wall Street Target
21 USD
69.49%
MYGN Average Price Target
Wall Street Target
29.7 USD
139.82%
MYGN Highest Price Target
Wall Street Target
35 USD
182.49%
REVENUE FORECAST
Revenue Forecast Chart MYGN
EBIT FORECAST
EBIT Forecast Chart MYGN
NET INCOME FORECAST
Net Income Chart MYGN